Continuing ICTI’s leadership in Adaptive Clinical Trial Design and Implementation, ICTI’s Manager of Biostatistics, Eva Miller, Ph.D., has been invited to present at the upcoming meeting of the International Society for Analysis, its Applications, and Computation (ISAAC).
Yardley, PA – July 19, 2005 – Continuing ICTI's leadership in Adaptive Clinical Trial Design and Implementation, ICTI's Manager of Biostatistics, Eva Miller, Ph.D., has been invited to present at the upcoming meeting of the International Society for Analysis, its Applications, and Computation (ISAAC). The 5Th annual conference, being held July 25-30, 2005 in Catania, Italy, includes a sub-session on Mathematical Biology and Medicine, in which Dr. Miller will present her talk, "Implementation of Adaptive Randomizations for Clinical Trials."
Because of the efficiencies they allow, adaptive trial designs are increasingly being used by both small biotechs and large pharmaceutical companies. Adaptive randomizations, a type of adaptive trial design, are especially valuable when study populations are small or when blinding of study drug/device vs. placebo is not possible. They are often used in studies of rare diseases, in oncology studies, and in medical device trials. Dr. Miller's presentation will recount ICTI's experience in working with clients to design and execute adaptive clinical trial designs.
Richard McCann, ICTI's President, noted, "Our unique combination of technologies for real-time clinical trial data capture, along with the capabilities of our sister company Clinical Trial Services (CTS) to provide state-of-the-art clinical supplies management positions ICTI to make adaptive clinical trial designs feasible. We are honored to have our capabilities and experience presented at this prestigious conference."
About ICTI and Almac Sciences
ICTI has been implementing adaptive randomization designs since 1999, and its technologies and services have been used in over 60 adaptive randomization studies. ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; iDiary phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.
Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and ArraDx (Array Based Diagnostics)) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.